

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

**INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC
FOR THE FULL CIRCULATION OF SHARES BY THE COMPANY**

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules, namely under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Reference is made to the circular of the Company dated 2 May 2025 (the “**Circular**”) in respect of the extraordinary general meeting, the poll result announcement dated 23 May 2025 and the announcement of the Company dated 26 May 2025 in relation to the submission of the Application to the CSRC in respect of the H Share Full Circulation (the “**Announcements**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular and the Announcements.

The Board is pleased to announce that the Company has received a filing notice (the “**Filing Notice**”) issued by the CSRC on 5 February 2026 in respect of the Application. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the implementation of the H Share Full Circulation. The Filing Notice will be valid for 12 months from the date of the issuance of the Filing Notice. The Company will apply to the Stock Exchange for the Conversion and Listing.

As at the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalised. The Company will make further announcements on the progress and details of the Conversion and Listing in compliance with the requirements under the Listing Rules and the applicable laws, as and when appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 6 February 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.